AstraZeneca vaccine and mRNA vaccine are equally effective in preventing hospitalization and death from COVID-19-Health

Newly evaluated data show that the AstraZeneca vaccine as well as the mRNA-based vaccines are equally protective in preventing hospitalization and death from COVID-19.

The above information was given by experts at the Asia Regional Webinar on “Protective efficacy of COVID-19 vaccines” taking place on April 27.

At the seminar Professor Guy Thwaites – Director of the Clinical Research Unit of Oxford University in Vietnam, shared that COVID-19 vaccines play a particularly important role in protecting people’s lives as well as in protecting people’s lives. such as helping countries in Southeast Asia partially return to normal in the past year.

The expert assessment found that the AstraZeneca vaccine and other mRNA vaccines currently available provide equal and high protection against the life-threatening risks of COVID-19.

Newly evaluated data show that the AstraZeneca vaccine as well as the mRNA-based vaccines are equally protective in preventing hospitalization and death from COVID-19.

“This will be important information for policymakers in the region, as they consider the optimal implementation plan of the COVID-19 vaccination program for people in each country in the next 12 months.” – Professor Guy Thwaites said.

Assoc. Prof. Dr. Do Van Dung – Dean of the Faculty of Public Health, University of Medicine and Pharmacy in Ho Chi Minh City, said that the ability to protect the body against serious developments of COVID-19 is the most important measure to evaluate vaccine effectiveness. COVID-19.

After vaccination, the level of antibodies in the blood will gradually decrease over time, but the body’s other defense mechanisms do not decline as quickly. They will help the body fight off the virus, thereby reducing the risk of serious consequences.

It can be reassuring to see that the effectiveness of preventing hospitalizations and deaths is comparable to that of the most widely used COVID-19 vaccines.

A recent expert review of data from 79 real-life studies found that two doses of today’s most popular vaccines, the AstraZeneca COVID-19 vaccine and the mRNA-based vaccines, resulted showed comparable protective efficacy in preventing COVID-19 hospitalizations and deaths.

The data above was evaluated by infectious disease experts across Asia and comes from VIEW-hub, an interactive platform that visualizes global data on usage and impacts. vaccine, developed by the John Hopkins Bloomberg School of Public Health and the International Vaccine Access Center (IVAC), USA. The platform is updated weekly to include real-life studies on vaccine effectiveness.

AstraZeneca’s vaccine is a viral vector vaccine – using a non-pathogenic version of the virus as part of the vaccine, teaching the body how to fight off disease if subsequently exposed to the real virus. Scientists have used this vaccine technology for the past 40 years to prevent other infectious diseases such as influenza, Zika, Ebola and HIV.

AstraZeneca and its global partners have delivered more than 2.9 billion doses of vaccine to more than 180 countries, of which about two-thirds have gone to low- and middle-income countries. It is estimated that AstraZeneca’s vaccine has prevented 50 million COVID-19 infections, 5 million hospitalizations and saved the lives of more than 1 million people.

To date, Vietnam has received more than 239 million doses of COVID-19 vaccine, of which mRNA technology has the largest number, followed by AstraZeneca vaccine and other vaccines. Vietnam has injected more than 213 million doses of vaccines of all kinds.